InfuSystem (NYSEAMERICAN:INFU) Upgraded at StockNews.com

StockNews.com upgraded shares of InfuSystem (NYSEAMERICAN:INFU) from a buy rating to a strong-buy rating in a research report released on Wednesday.

InfuSystem Trading Up 4.6 %

NYSEAMERICAN:INFU opened at $8.15 on Wednesday. InfuSystem has a 1-year low of $7.75 and a 1-year high of $11.44. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.54 and a current ratio of 1.95. The firm has a market capitalization of $173.27 million, a P/E ratio of 271.76 and a beta of 1.24.

Institutional Investors Weigh In On InfuSystem

Several institutional investors have recently made changes to their positions in INFU. Panagora Asset Management Inc. boosted its position in shares of InfuSystem by 1.7% during the 1st quarter. Panagora Asset Management Inc. now owns 87,948 shares of the medical instruments supplier’s stock worth $862,000 after purchasing an additional 1,508 shares in the last quarter. Rhumbline Advisers raised its stake in shares of InfuSystem by 44.8% during the 1st quarter. Rhumbline Advisers now owns 16,232 shares of the medical instruments supplier’s stock worth $159,000 after buying an additional 5,021 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of InfuSystem by 18.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 313,148 shares of the medical instruments supplier’s stock worth $3,069,000 after buying an additional 49,546 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of InfuSystem by 8.6% during the 1st quarter. Vanguard Group Inc. now owns 859,052 shares of the medical instruments supplier’s stock worth $8,418,000 after buying an additional 68,242 shares during the last quarter. Finally, Wasatch Advisors Inc. raised its stake in shares of InfuSystem by 18.6% during the 1st quarter. Wasatch Advisors Inc. now owns 859,679 shares of the medical instruments supplier’s stock worth $8,425,000 after buying an additional 135,076 shares during the last quarter. 71.13% of the stock is currently owned by hedge funds and other institutional investors.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.